Difficulty: Medium
Average Score: 95%
Practice
Which of the following drugs is an insulin secretagogue:
Correct answer
C
Rationale
Insulin secretagogues stimulate pancreatic beta cells to release insulin. Repaglinide (choice C), a meglitinide, does this by closing ATP-sensitive potassium channels, depolarizing beta cells, and triggering insulin secretion, useful in type 2 diabetes for postprandial glucose control. Metformin (choice A), a biguanide, reduces hepatic glucose production and improves insulin sensitivity, not secretion. Pioglitazone (choice B), a thiazolidinedione, enhances insulin sensitivity in peripheral tissues, not directly stimulating insulin release. Hydrochlorothiazide (choice D), a diuretic, affects blood pressure and electrolytes, unrelated to insulin secretion. Repaglinide's mechanism aligns with the secretagogue definition, distinguishing it from other antidiabetic classes. This understanding is crucial for tailoring therapy to patient needs, especially in managing hyperglycemia effectively while avoiding hypoglycemia risks associated with secretagogues.